AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Jonathan Strober, MD, discusses advancements in pediatric myasthenia gravis, emphasizing the need for better treatment standards and effective patient care strategies. In this conclusion of a recent ...
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...
Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...
What Is Uplizna, and Why Does It Matter? Uplizna (inebilizumab-cdon) is a prescription medicine recently approved by the FDA to treat adults with generalized myasthenia gravis (gMG) who test positive ...
The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...
SAN FRANCISCO — Efgartigimod (Vyvgart), a neonatal Fc receptor (FcRn) antagonist, significantly improved symptoms in patients with anti-acetylcholine receptor antibody (AChR-Ab)-negative generalized ...
—Using an extensive lifestyle and environment questionnaire, investigators in Sweden sought to identify additional risk factors for myasthenia gravis (MG), focusing on nicotine and alcohol consumption ...
A new retrospective analysis compared clinical features of White, Hispanic, and African-American patients with MG who visited a single university-based clinic. After adjusting for covariates, the ...
Clinicians in Europe may soon gain access to a first-in-class neonatal Fc receptor (FcRn) inhibitor for generalized myasthenia gravis (gMG). Imaavy (nipocalimab; Janssen-Cilag International) received ...
Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback